Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
Male patients with von Willebrand disease were more likely to be diagnosed earlier and to report bleeds compared with female patients.
Researchers conducted a meta-analysis of 23 studies to determine the influence of measurable residual disease on survival outcomes.
Researchers analyzed long-term safety and efficacy data from patients treated with ibrutinib or ofatumumab in the phase 3 RESONATE trial.
Time to initiation of therapy was significantly longer for black and Hispanic patients compared with white patients.
Compared with white patients, Hispanic and non-Hispanic black patients had significantly poorer rates of postrelapse overall survival.
Researchers conducted a meta-analysis to evaluate possible associations between certain genetic variants and risk for acute lymphoblastic leukemia.
Red blood cell distribution width above the calculated cutoff of 13.8% was significantly associated with poorer overall survival.
A review and meta-analysis of 25 randomized controlled trials showed that single-agent treatment strategies were generally more effective than combination strategies.
Older age at diagnosis, white race, and body mass index below the fifth percentile were associated with low bone mineral density.
